Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors

Authors:

Abstract
As of January 2021, pembrolizumab has received 39 US Food and Drug Administration (FDA) approvals for the treatment of cancer. Initially approved with weight-based dosing, there was a subsequent movement toward using fixed doses for all patients, first with 200 mg every 3 weeks, and more recently 400 mg every 6 weeks.1 It has previously been argued that the move to fixed dosing from weight-based dosing has maintained efficacy but increased costs.2 While lower doses of immune checkpoint inhibitors have been strongly recommended in other publications,3-5 we recognize that the FDA-approved dose levels and schedules remain the standard of care in many health care settings.

This publication has 9 references indexed in Scilit: